This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Birx, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascola, J. R.
Right arrow Articles by Birx, D. L.

 Previous Article  |  Next Article 

Journal of Virology, May 1999, p. 4009-4018, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

John R. Mascola,1,* Mark G. Lewis,1 Gabriela Stiegler,2 Dawn Harris,1 Thomas C. VanCott,1 Deborah Hayes,1 Mark K. Louder,1 Charles R. Brown,3 Christine V. Sapan,4 Sarah S. Frankel,1 Yichen Lu,5 Merlin L. Robb,1 Hermann Katinger,2 and Deborah L. Birx1

Division of Retrovirology, Walter Reed Army Institute of Research and Henry M. Jackson Foundation, Rockville, Maryland 208501; Institute of Applied Microbiology, University of Agriculture, Vienna, Austria2; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland 208523; NABI, Boca Raton, Florida 334874; and AVANT Immunotherapeutics, Needham, Massachusetts 02494-27255

Received 2 December 1998/Accepted 27 January 1999

The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using a chimeric simian/human immunodeficiency virus (SHIV) based on the envelope of a primary isolate (HIV-89.6), we performed passive-transfer experiments in rhesus macaques to study the role of anti-envelope antibodies in protection. Based on prior in vitro data showing neutralization synergy by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies (MAbs) 2F5 and 2G12 given alone, compared with the double combination 2F5/2G12 and the triple combination HIVIG/2F5/2G12. Antibodies were administered 24 h prior to intravenous challenge with the pathogenic SHIV-89.6PD. Six control monkeys displayed high plasma viremia, rapid CD4+-cell decline, and clinical AIDS within 14 weeks. Of six animals given HIVIG/2F5/2G12, three were completely protected; the remaining three animals became SHIV infected but displayed reduced plasma viremia and near normal CD4+-cell counts. One of three monkeys given 2F5/2G12 exhibited only transient evidence of infection; the other two had marked reductions in viral load. All monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed high-level plasma viremia. However, compared to controls, monkeys that received HIVIG or MAb 2G12 displayed a less profound drop in CD4+ T cells and a more benign clinical course. These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease.

* Corresponding author. Mailing address: Division of Retrovirology, Walter Reed Army Institute of Research, 1 Taft Court, Suite 250, Rockville, MD 20850. Phone: (301) 294-1888. Fax: (301) 294-1898. E-mail: jmascola{at}hiv.hjf.org.

Journal of Virology, May 1999, p. 4009-4018, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., Birungi, J., Pozniak, A., McPhee, D. A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., DeHovitz, J., Bekker, L.-G., Pitisuttithum, P., Paris, R., Walker, L. M., Poignard, P., Wrin, T., Fast, P. E., Burton, D. R., Koff, W. C. (2009). Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. J. Virol. 83: 7337-7348 [Abstract] [Full Text]  
  • Ourmanov, I., Kuwata, T., Goeken, R., Goldstein, S., Iyengar, R., Buckler-White, A., Lafont, B., Hirsch, V. M. (2009). Improved Survival in Rhesus Macaques Immunized with Modified Vaccinia Virus Ankara Recombinants Expressing Simian Immunodeficiency Virus Envelope Correlates with Reduction in Memory CD4+ T-Cell Loss and Higher Titers of Neutralizing Antibody. J. Virol. 83: 5388-5400 [Abstract] [Full Text]  
  • Arnold, G. F., Velasco, P. K., Holmes, A. K., Wrin, T., Geisler, S. C., Phung, P., Tian, Y., Resnick, D. A., Ma, X., Mariano, T. M., Petropoulos, C. J., Taylor, J. W., Katinger, H., Arnold, E. (2009). Broad Neutralization of Human Immunodeficiency Virus Type 1 (HIV-1) Elicited from Human Rhinoviruses That Display the HIV-1 gp41 ELDKWA Epitope. J. Virol. 83: 5087-5100 [Abstract] [Full Text]  
  • Hidajat, R., Xiao, P., Zhou, Q., Venzon, D., Summers, L. E., Kalyanaraman, V. S., Montefiori, D. C., Robert-Guroff, M. (2009). Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge of Rhesus Macaques. J. Virol. 83: 791-801 [Abstract] [Full Text]  
  • Doria-Rose, N. A., Klein, R. M., Manion, M. M., O'Dell, S., Phogat, A., Chakrabarti, B., Hallahan, C. W., Migueles, S. A., Wrammert, J., Ahmed, R., Nason, M., Wyatt, R. T., Mascola, J. R., Connors, M. (2009). Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. J. Virol. 83: 188-199 [Abstract] [Full Text]  
  • Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., Cohen, M., Eron, J., Hicks, C. B., Liao, H.-X., Self, S. G., Landucci, G., Forthal, D. N., Weinhold, K. J., Keele, B. F., Hahn, B. H., Greenberg, M. L., Morris, L., Karim, S. S. A., Blattner, W. A., Montefiori, D. C., Shaw, G. M., Perelson, A. S., Haynes, B. F. (2008). Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. J. Virol. 82: 12449-12463 [Abstract] [Full Text]  
  • Blish, C. A., Dogan, O. C., Derby, N. R., Nguyen, M.-A., Chohan, B., Richardson, B. A., Overbaugh, J. (2008). Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses. J. Virol. 82: 12094-12103 [Abstract] [Full Text]  
  • Laird, M. E., Igarashi, T., Martin, M. A., Desrosiers, R. C. (2008). Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response. J. Virol. 82: 11054-11065 [Abstract] [Full Text]  
  • Demberg, T., Boyer, J. D., Malkevich, N., Patterson, L. J., Venzon, D., Summers, E. L., Kalisz, I., Kalyanaraman, V. S., Lee, E. M., Weiner, D. B., Robert-Guroff, M. (2008). Sequential Priming with Simian Immunodeficiency Virus (SIV) DNA Vaccines, with or without Encoded Cytokines, and a Replicating Adenovirus-SIV Recombinant Followed by Protein Boosting Does Not Control a Pathogenic SIVmac251 Mucosal Challenge. J. Virol. 82: 10911-10921 [Abstract] [Full Text]  
  • Vaine, M., Wang, S., Crooks, E. T., Jiang, P., Montefiori, D. C., Binley, J., Lu, S. (2008). Improved Induction of Antibodies against Key Neutralizing Epitopes by Human Immunodeficiency Virus Type 1 gp120 DNA Prime-Protein Boost Vaccination Compared to gp120 Protein-Only Vaccination. J. Virol. 82: 7369-7378 [Abstract] [Full Text]  
  • Astronomo, R. D., Lee, H.-K., Scanlan, C. N., Pantophlet, R., Huang, C.-Y., Wilson, I. A., Blixt, O., Dwek, R. A., Wong, C.-H., Burton, D. R. (2008). A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. J. Virol. 82: 6359-6368 [Abstract] [Full Text]  
  • Duval, M., Posner, M. R., Cavacini, L. A. (2008). A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils. J. Virol. 82: 4671-4674 [Abstract] [Full Text]  
  • Menendez, A., Calarese, D. A., Stanfield, R. L., Chow, K. C., Scanlan, C. N., Kunert, R., Katinger, H., Burton, D. R., Wilson, I. A., Scott, J. K. (2008). A peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120. FASEB J. 22: 1380-1392 [Abstract] [Full Text]  
  • Tagmyer, T. L., Craigo, J. K., Cook, S. J., Even, D. L., Issel, C. J., Montelaro, R. C. (2008). Envelope Determinants of Equine Infectious Anemia Virus Vaccine Protection and the Effects of Sequence Variation on Immune Recognition. J. Virol. 82: 4052-4063 [Abstract] [Full Text]  
  • Montero, M., van Houten, N. E., Wang, X., Scott, J. K. (2008). The Membrane-Proximal External Region of the Human Immunodeficiency Virus Type 1 Envelope: Dominant Site of Antibody Neutralization and Target for Vaccine Design. Microbiol. Mol. Biol. Rev. 72: 54-84 [Abstract] [Full Text]  
  • DeVico, A., Fouts, T., Lewis, G. K., Gallo, R. C., Godfrey, K., Charurat, M., Harris, I., Galmin, L., Pal, R. (2007). Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. USA 104: 17477-17482 [Abstract] [Full Text]  
  • Mehandru, S., Vcelar, B., Wrin, T., Stiegler, G., Joos, B., Mohri, H., Boden, D., Galovich, J., Tenner-Racz, K., Racz, P., Carrington, M., Petropoulos, C., Katinger, H., Markowitz, M. (2007). Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection. J. Virol. 81: 11016-11031 [Abstract] [Full Text]  
  • Gray, E. S., Moore, P. L., Pantophlet, R. A., Morris, L. (2007). N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. J. Virol. 81: 10769-10776 [Abstract] [Full Text]  
  • Quakkelaar, E. D., van Alphen, F. P. J., Boeser-Nunnink, B. D. M., van Nuenen, A. C., Pantophlet, R., Schuitemaker, H. (2007). Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies. J. Virol. 81: 8533-8542 [Abstract] [Full Text]  
  • Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F.-H., Richman, D. D., Doms, R. W., Vanham, G., Burton, D. R. (2007). Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. J. Virol. 81: 6548-6562 [Abstract] [Full Text]  
  • Sack, M., Paetz, A., Kunert, R., Bomble, M., Hesse, F., Stiegler, G., Fischer, R., Katinger, H., Stoeger, E., Rademacher, T. (2007). Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J. 21: 1655-1664 [Abstract] [Full Text]  
  • Johnston, M. I., Fauci, A. S. (2007). An HIV Vaccine -- Evolving Concepts. NEJM 356: 2073-2081 [Full Text]  
  • Miller, C. J., Genesca, M., Abel, K., Montefiori, D., Forthal, D., Bost, K., Li, J., Favre, D., McCune, J. M. (2007). Antiviral Antibodies Are Necessary for Control of Simian Immunodeficiency Virus Replication. J. Virol. 81: 5024-5035 [Abstract] [Full Text]  
  • Forthal, D. N., Gilbert, P. B., Landucci, G., Phan, T. (2007). Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. J. Immunol. 178: 6596-6603 [Abstract] [Full Text]  
  • Fernando, K., Hu, H., Ni, H., Hoxie, J. A., Weissman, D. (2007). Vaccine-delivered HIV envelope inhibits CD4+ T-cell activation, a mechanism for poor HIV vaccine responses. Blood 109: 2538-2544 [Abstract] [Full Text]  
  • Florese, R. H., Van Rompay, K. K. A., Aldrich, K., Forthal, D. N., Landucci, G., Mahalanabis, M., Haigwood, N., Venzon, D., Kalyanaraman, V. S., Marthas, M. L., Robert-Guroff, M. (2006). Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge. J. Immunol. 177: 4028-4036 [Abstract] [Full Text]  
  • Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M., Stamatatos, L. (2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.. J. Virol. 80: 8745-8762 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Cole, K. S., Marthas, M., Becerra, J. C., Van Rompay, K. (2006). Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.. J. Virol. 80: 9217-9225 [Abstract] [Full Text]  
  • Margolin, D. H., Saunders, E. H., Bronfin, B., de Rosa, N., Axthelm, M. K., Goloubeva, O. G., Eapen, S., Gelman, R. S., Letvin, N. L. (2006). Germinal Center Function in the Spleen during Simian HIV Infection in Rhesus Monkeys. J. Immunol. 177: 1108-1119 [Abstract] [Full Text]  
  • Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H., Makizumi, K., Nakashima, T., Osatomi, K., Tokiyoshi, S., Matsushita, S., Yamamoto, N., Honda, M. (2006). Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif.. J. Virol. 80: 5552-5562 [Abstract] [Full Text]  
  • Eda, Y., Murakami, T., Ami, Y., Nakasone, T., Takizawa, M., Someya, K., Kaizu, M., Izumi, Y., Yoshino, N., Matsushita, S., Higuchi, H., Matsui, H., Shinohara, K., Takeuchi, H., Koyanagi, Y., Yamamoto, N., Honda, M. (2006). Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection.. J. Virol. 80: 5563-5570 [Abstract] [Full Text]  
  • Joos, B., Trkola, A., Kuster, H., Aceto, L., Fischer, M., Stiegler, G., Armbruster, C., Vcelar, B., Katinger, H., Gunthard, H. F. (2006). Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).. Antimicrob. Agents Chemother. 50: 1773-1779 [Abstract] [Full Text]  
  • Lauren, A., Thorstensson, R., Fenyo, E. M. (2006). Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease.. J. Gen. Virol. 87: 595-606 [Abstract] [Full Text]  
  • Hammonds, J., Chen, X., Fouts, T., DeVico, A., Montefiori, D., Spearman, P. (2005). Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization. J. Virol. 79: 14804-14814 [Abstract] [Full Text]  
  • Mao, H., Lafont, B. A. P., Igarashi, T., Nishimura, Y., Brown, C., Hirsch, V., Buckler-White, A., Sadjadpour, R., Martin, M. A. (2005). CD8+ and CD20+ Lymphocytes Cooperate To Control Acute Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys: Modulation by Major Histocompatibility Complex Genotype. J. Virol. 79: 14887-14898 [Abstract] [Full Text]  
  • Lian, Y., Srivastava, I., Gomez-Roman, V. R., zur Megede, J., Sun, Y., Kan, E., Hilt, S., Engelbrecht, S., Himathongkham, S., Luciw, P. A., Otten, G., Ulmer, J. B., Donnelly, J. J., Rabussay, D., Montefiori, D., van Rensburg, E. J., Barnett, S. W. (2005). Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain. J. Virol. 79: 13338-13349 [Abstract] [Full Text]  
  • Steckbeck, J. D., Orlov, I., Chow, A., Grieser, H., Miller, K., Bruno, J., Robinson, J. E., Montelaro, R. C., Cole, K. S. (2005). Kinetic Rates of Antibody Binding Correlate with Neutralization Sensitivity of Variant Simian Immunodeficiency Virus Strains. J. Virol. 79: 12311-12320 [Abstract] [Full Text]  
  • Raviv, Y., Viard, M., Bess, J. W Jr., Chertova, E., Blumenthal, R. (2005). Inactivation of Retroviruses with Preservation of Structural Integrity by Targeting the Hydrophobic Domain of the Viral Envelope. J. Virol. 79: 12394-12400 [Abstract] [Full Text]  
  • Skrabal, K., Saragosti, S., Labernardiere, J.-L., Barin, F., Clavel, F., Mammano, F. (2005). Human Immunodeficiency Virus Type 1 Variants Isolated from Single Plasma Samples Display a Wide Spectrum of Neutralization Sensitivity. J. Virol. 79: 11848-11857 [Abstract] [Full Text]  
  • Forsell, M. N. E., Li, Y., Sundback, M., Svehla, K., Liljestrom, P., Mascola, J. R., Wyatt, R., Hedestam, G. B. K. (2005). Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. J. Virol. 79: 10902-10914 [Abstract] [Full Text]  
  • Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K. M., Bilska, M., Kothe, D. L., Salazar-Gonzalez, J. F., Wei, X., Decker, J. M., Hahn, B. H., Montefiori, D. C. (2005). Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. J. Virol. 79: 10108-10125 [Abstract] [Full Text]  
  • Schmitz, J. E., Johnson, R. P., McClure, H. M., Manson, K. H., Wyand, M. S., Kuroda, M. J., Lifton, M. A., Khunkhun, R. S., McEvers, K. J., Gillis, J., Piatak, M., Lifson, J. D., Grosschupff, G., Racz, P., Tenner-Racz, K., Rieber, E. P., Kuus-Reichel, K., Gelman, R. S., Letvin, N. L., Montefiori, D. C., Ruprecht, R. M., Desrosiers, R. C., Reimann, K. A. (2005). Effect of CD8+ Lymphocyte Depletion on Virus Containment after Simian Immunodeficiency Virus SIVmac251 Challenge of Live Attenuated SIVmac239{Delta}3-Vaccinated Rhesus Macaques. J. Virol. 79: 8131-8141 [Abstract] [Full Text]  
  • Otten, G. R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., zur Megede, J., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., Montefiori, D., Lewis, M., Driver, D. A., Dubensky, T., Polo, J. M., Donnelly, J., O'Hagan, D. T., Barnett, S., Ulmer, J. B. (2005). Enhanced Potency of Plasmid DNA Microparticle Human Immunodeficiency Virus Vaccines in Rhesus Macaques by Using a Priming-Boosting Regimen with Recombinant Proteins. J. Virol. 79: 8189-8200 [Abstract] [Full Text]  
  • Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
  • Buonaguro, L., Visciano, M. L., Tornesello, M. L., Tagliamonte, M., Biryahwaho, B., Buonaguro, F. M. (2005). Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation. J. Virol. 79: 7059-7067 [Abstract] [Full Text]  
  • Brown, B. K., Darden, J. M., Tovanabutra, S., Oblander, T., Frost, J., Sanders-Buell, E., de Souza, M. S., Birx, D. L., McCutchan, F. E., Polonis, V. R. (2005). Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines. J. Virol. 79: 6089-6101 [Abstract] [Full Text]  
  • Gros, L., Dreja, H., Fiser, A. L., Plays, M., Pelegrin, M., Piechaczyk, M. (2005). Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment. J. Virol. 79: 6272-6280 [Abstract] [Full Text]  
  • Quinnan, G. V. Jr., Yu, X.-F., Lewis, M. G., Zhang, P. F., Sutter, G., Silvera, P., Dong, M., Choudhary, A., Sarkis, P. T. N., Bouma, P., Zhang, Z., Montefiori, D. C., VanCott, T. C., Broder, C. C. (2005). Protection of Rhesus Monkeys against Infection with Minimally Pathogenic Simian-Human Immunodeficiency Virus: Correlations with Neutralizing Antibodies and Cytotoxic T Cells. J. Virol. 79: 3358-3369 [Abstract] [Full Text]  
  • Singh, D. K., Liu, Z., Sheffer, D., Mackay, G. A., Smith, M., Dhillon, S., Hegde, R., Jia, F., Adany, I., Narayan, O. (2005). A Noninfectious Simian/Human Immunodeficiency Virus DNA Vaccine That Protects Macaques against AIDS. J. Virol. 79: 3419-3428 [Abstract] [Full Text]  
  • Yang, X., Kurteva, S., Lee, S., Sodroski, J. (2005). Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1. J. Virol. 79: 3500-3508 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Phan, T. B., Becerra, J. (2005). Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J. Virol. 79: 2042-2049 [Abstract] [Full Text]  
  • Lenz, O., Dittmar, M. T., Wagner, A., Ferko, B., Vorauer-Uhl, K., Stiegler, G., Weissenhorn, W. (2005). Trimeric Membrane-anchored gp41 Inhibits HIV Membrane Fusion. J. Biol. Chem. 280: 4095-4101 [Abstract] [Full Text]  
  • Mehandru, S., Wrin, T., Galovich, J., Stiegler, G., Vcelar, B., Hurley, A., Hogan, C., Vasan, S., Katinger, H., Petropoulos, C. J., Markowitz, M. (2004). Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10. J. Virol. 78: 14039-14042 [Abstract] [Full Text]  
  • Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J., Burton, D. R. (2004). Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. J. Virol. 78: 13232-13252 [Abstract] [Full Text]  
  • Dacheux, L., Moreau, A., Ataman-Onal, Y., Biron, F., Verrier, B., Barin, F. (2004). Evolutionary Dynamics of the Glycan Shield of the Human Immunodeficiency Virus Envelope during Natural Infection and Implications for Exposure of the 2G12 Epitope. J. Virol. 78: 12625-12637 [Abstract] [Full Text]  
  • Holl, V., Hemmerter, S., Burrer, R., Schmidt, S., Bohbot, A., Aubertin, A.-M., Moog, C. (2004). Involvement of Fc{gamma}R I (CD64) in the Mechanism of HIV-1 Inhibition by Polyclonal IgG Purified from Infected Patients in Cultured Monocyte-Derived Macrophages. J. Immunol. 173: 6274-6283 [Abstract] [Full Text]  
  • Armbruster, C., Stiegler, G. M., Vcelar, B. A., Jager, W., Koller, U., Jilch, R., Ammann, C. G., Pruenster, M., Stoiber, H., Katinger, H. W. D. (2004). Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 54: 915-920 [Abstract] [Full Text]  
  • Zhang, M.-Y., Xiao, X., Sidorov, I. A., Choudhry, V., Cham, F., Zhang, P. F., Bouma, P., Zwick, M., Choudhary, A., Montefiori, D. C., Broder, C. C., Burton, D. R., Quinnan, G. V. Jr., Dimitrov, D. S. (2004). Identification and Characterization of a New Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody. J. Virol. 78: 9233-9242 [Abstract] [Full Text]  
  • Publicover, J., Ramsburg, E., Rose, J. K. (2004). Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses. J. Virol. 78: 9317-9324 [Abstract] [Full Text]  
  • Makitalo, B., Lundholm, P., Hinkula, J., Nilsson, C., Karlen, K., Morner, A., Sutter, G., Erfle, V., Heeney, J. L., Wahren, B., Biberfeld, G., Thorstensson, R. (2004). Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol. 85: 2407-2419 [Abstract] [Full Text]  
  • Yao, Q., Zhang, R., Guo, L., Li, M., Chen, C. (2004). Th Cell-Independent Immune Responses to Chimeric Hemagglutinin/Simian Human Immunodeficiency Virus-Like Particles Vaccine. J. Immunol. 173: 1951-1958 [Abstract] [Full Text]  
  • Zhang, L., Ribeiro, R. M., Mascola, J. R., Lewis, M. G., Stiegler, G., Katinger, H., Perelson, A. S., Davenport, M. P. (2004). Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. J. Virol. 78: 5520-5522 [Abstract] [Full Text]  
  • Davis, C. W., Doms, R. W. (2004). HIV Transmission: Closing All the Doors. JEM 199: 1037-1040 [Full Text]  
  • Mooij, P., Nieuwenhuis, I. G., Knoop, C. J., Doms, R. W., Bogers, W. M. J. M., ten Haaft, P. J. F., Niphuis, H., Koornstra, W., Bieler, K., Kostler, J., Morein, B., Cafaro, A., Ensoli, B., Wagner, R., Heeney, J. L. (2004). Qualitative T-Helper Responses to Multiple Viral Antigens Correlate with Vaccine-Induced Immunity to Simian/Human Immunodeficiency Virus Infection. J. Virol. 78: 3333-3342 [Abstract] [Full Text]  
  • Zwick, M. B., Komori, H. K., Stanfield, R. L., Church, S., Wang, M., Parren, P. W. H. I., Kunert, R., Katinger, H., Wilson, I. A., Burton, D. R. (2004). The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5. J. Virol. 78: 3155-3161 [Abstract] [Full Text]  
  • Bertley, F. M. N., Kozlowski, P. A., Wang, S.-W., Chappelle, J., Patel, J., Sonuyi, O., Mazzara, G., Montefiori, D., Carville, A., Mansfield, K. G., Aldovini, A. (2004). Control of Simian/Human Immunodeficiency Virus Viremia and Disease Progression after IL-2-Augmented DNA-Modified Vaccinia Virus Ankara Nasal Vaccination in Nonhuman Primates. J. Immunol. 172: 3745-3757 [Abstract] [Full Text]  
  • Nishimura, Y., Igarashi, T., Haigwood, N. L., Sadjadpour, R., Donau, O. K., Buckler, C., Plishka, R. J., Buckler-White, A., Martin, M. A. (2003). Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 100: 15131-15136 [Abstract] [Full Text]  
  • Srivastava, I. K., Stamatatos, L., Kan, E., Vajdy, M., Lian, Y., Hilt, S., Martin, L., Vita, C., Zhu, P., Roux, K. H., Vojtech, L., C. Montefiori, D., Donnelly, J., Ulmer, J. B., Barnett, S. W. (2003). Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate. J. Virol. 77: 11244-11259 [Abstract] [Full Text]  
  • Mascola, J. R., Lewis, M. G., VanCott, T. C., Stiegler, G., Katinger, H., Seaman, M., Beaudry, K., Barouch, D. H., Korioth-Schmitz, B., Krivulka, G., Sambor, A., Welcher, B., Douek, D. C., Montefiori, D. C., Shiver, J. W., Poignard, P., Burton, D. R., Letvin, N. L. (2003). Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies. J. Virol. 77: 10348-10356 [Abstract] [Full Text]  
  • Patterson, L. J., Malkevitch, N., Pinczewski, J., Venzon, D., Lou, Y., Peng, B., Munch, C., Leonard, M., Richardson, E., Aldrich, K., Kalyanaraman, V. S., Pavlakis, G. N., Robert-Guroff, M. (2003). Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120. J. Virol. 77: 8607-8620 [Abstract] [Full Text]  
  • Zhao, J., Pinczewski, J., Gomez-Roman, V. R., Venzon, D., Kalyanaraman, V. S., Markham, P. D., Aldrich, K., Moake, M., Montefiori, D. C., Lou, Y., Pavlakis, G. N., Robert-Guroff, M. (2003). Improved Protection of Rhesus Macaques against Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge by a Replication-Competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag Recombinant Priming/gp120 Boosting Regimen. J. Virol. 77: 8354-8365 [Abstract] [Full Text]  
  • Painter, S. L., Biek, R., Holley, D. C., Poss, M. (2003). Envelope Variants from Women Recently Infected with Clade A Human Immunodeficiency Virus Type 1 Confer Distinct Phenotypes That Are Discerned by Competition and Neutralization Experiments. J. Virol. 77: 8448-8461 [Abstract] [Full Text]  
  • zur Megede, J., Otten, G. R., Doe, B., Liu, H., Leung, L., Ulmer, J. B., Donnelly, J. J., Barnett, S. W. (2003). Expression and Immunogenicity of Sequence-Modified Human Immunodeficiency Virus Type 1 Subtype B pol and gagpol DNA Vaccines. J. Virol. 77: 6197-6207 [Abstract] [Full Text]  
  • Zwick, M. B., Parren, P. W. H. I., Saphire, E. O., Church, S., Wang, M., Scott, J. K., Dawson, P. E., Wilson, I. A., Burton, D. R. (2003). Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120. J. Virol. 77: 5863-5876 [Abstract] [Full Text]  
  • Otten, G., Schaefer, M., Greer, C., Calderon-Cacia, M., Coit, D., Kazzaz, J., Medina-Selby, A., Selby, M., Singh, M., Ugozzoli, M., zur Megede, J., Barnett, S. W., O'Hagan, D., Donnelly, J., Ulmer, J. (2003). Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles. J. Virol. 77: 6087-6092 [Abstract] [Full Text]  
  • Malkevitch, N., Patterson, L. J., Aldrich, K., Richardson, E., Alvord, W. G., Robert-Guroff, M. (2003). A Replication Competent Adenovirus 5 Host Range Mutant-Simian Immunodeficiency Virus (SIV) Recombinant Priming/Subunit Protein Boosting Vaccine Regimen Induces Broad, Persistent SIV-Specific Cellular Immunity to Dominant and Subdominant Epitopes in Mamu-A*01 Rhesus Macaques. J. Immunol. 170: 4281-4289 [Abstract] [Full Text]  
  • Wolbank, S., Kunert, R., Stiegler, G., Katinger, H. (2003). Characterization of Human Class-Switched Polymeric (Immunoglobulin M [IgM] and IgA) Anti-Human Immunodeficiency Virus Type 1 Antibodies 2F5 and 2G12. J. Virol. 77: 4095-4103 [Abstract] [Full Text]  
  • Stiegler, G., Katinger, H. (2003). Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 51: 757-759 [Full Text]  
  • Richman, D. D., Wrin, T., Little, S. J., Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100: 4144-4149 [Abstract] [Full Text]  
  • Montefiori, D. C., Altfeld, M., Lee, P. K., Bilska, M., Zhou, J., Johnston, M. N., Gao, F., Walker, B. D., Rosenberg, E. S. (2003). Viremia Control Despite Escape from a Rapid and Potent Autologous Neutralizing Antibody Response After Therapy Cessation in an HIV-1-Infected Individual. J. Immunol. 170: 3906-3914 [Abstract] [Full Text]  
  • Lopez-Bueno, A., Mateu, M. G., Almendral, J. M. (2003). High Mutant Frequency in Populations of a DNA Virus Allows Evasion from Antibody Therapy in an Immunodeficient Host. J. Virol. 77: 2701-2708 [Abstract] [Full Text]  
  • Schmitz, J. E., Kuroda, M. J., Santra, S., Simon, M. A., Lifton, M. A., Lin, W., Khunkhun, R., Piatak, M., Lifson, J. D., Grosschupff, G., Gelman, R. S., Racz, P., Tenner-Racz, K., Mansfield, K. A., Letvin, N. L., Montefiori, D. C., Reimann, K. A. (2003). Effect of Humoral Immune Responses on Controlling Viremia during Primary Infection of Rhesus Monkeys with Simian Immunodeficiency Virus. J. Virol. 77: 2165-2173 [Abstract] [Full Text]  
  • Voss, G., Manson, K., Montefiori, D., Watkins, D. I., Heeney, J., Wyand, M., Cohen, J., Bruck, C. (2002). Prevention of Disease Induced by a Partially Heterologous AIDS Virus in Rhesus Monkeys by Using an Adjuvanted Multicomponent Protein Vaccine. J. Virol. 77: 1049-1058 [Abstract] [Full Text]  
  • Herrera, C., Spenlehauer, C., Fung, M. S., Burton, D. R., Beddows, S., Moore, J. P. (2002). Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. J. Virol. 77: 1084-1091 [Abstract] [Full Text]  
  • Willey, R. L., Byrum, R., Piatak, M., Kim, Y. B., Cho, M. W., Rossio, J. L. Jr., Bess, J. Jr., Igarashi, T., Endo, Y., Arthur, L. O., Lifson, J. D., Martin, M. A. (2002). Control of Viremia and Prevention of Simian-Human Immunodeficiency Virus-Induced Disease in Rhesus Macaques Immunized with Recombinant Vaccinia Viruses plus Inactivated Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Particles. J. Virol. 77: 1163-1174 [Abstract] [Full Text]  
  • Poignard, P., Moulard, M., Golez, E., Vivona, V., Franti, M., Venturini, S., Wang, M., Parren, P. W. H. I., Burton, D. R. (2002). Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies. J. Virol. 77: 353-365 [Abstract] [Full Text]  
  • Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W. H. I., Wilson, I. A., Burton, D. R. (2002). Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. J. Virol. 77: 642-658 [Abstract] [Full Text]  
  • Jeffs, S. A., Shotton, C., Balfe, P., McKeating, J. A. (2002). Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J. Gen. Virol. 83: 2723-2732 [Abstract] [Full Text]  
  • Lewis, A. D., Chen, R., Montefiori, D. C., Johnson, P. R., Clark, K. R. (2002). Generation of Neutralizing Activity against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer. J. Virol. 76: 8769-8775 [Abstract] [Full Text]  
  • Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., Korber, B. (2002). Diversity Considerations in HIV-1 Vaccine Selection. Science 296: 2354-2360 [Abstract] [Full Text]  
  • Venturini, S., Mosier, D. E., Burton, D. R., Poignard, P. (2002). Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Gag- and Gag Peptide-Specific CD4+ T-Cell Clones from an HIV-1-Seronegative Donor following In Vitro Immunization. J. Virol. 76: 6987-6999 [Abstract] [Full Text]  
  • Horton, H., Vogel, T. U., Carter, D. K., Vielhuber, K., Fuller, D. H., Shipley, T., Fuller, J. T., Kunstman, K. J., Sutter, G., Montefiori, D. C., Erfle, V., Desrosiers, R. C., Wilson, N., Picker, L. J., Wolinsky, S. M., Wang, C., Allison, D. B., Watkins, D. I. (2002). Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239. J. Virol. 76: 7187-7202 [Abstract] [Full Text]  
  • Sanders, R. W., Venturi, M., Schiffner, L., Kalyanaraman, R., Katinger, H., Lloyd, K. O., Kwong, P. D., Moore, J. P. (2002). The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. J. Virol. 76: 7293-7305 [Abstract] [Full Text]  
  • Scanlan, C. N., Pantophlet, R., Wormald, M. R., Ollmann Saphire, E., Stanfield, R., Wilson, I. A., Katinger, H., Dwek, R. A., Rudd, P. M., Burton, D. R. (2002). The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of {alpha}1->2 Mannose Residues on the Outer Face of gp120. J. Virol. 76: 7306-7321 [Abstract] [Full Text]  
  • Subbramanian, R. A., Xu, J., Toma, E., Morisset, R., Cohen, E. A., Menezes,, J., Ahmad, A. (2002). Comparison of Human Immunodeficiency Virus (HIV)-Specific Infection-Enhancing and -Inhibiting Antibodies in AIDS Patients. J. Clin. Microbiol. 40: 2141-2146 [Abstract] [Full Text]  
  • Parren, P. W. H. I., Geisbert, T. W., Maruyama, T., Jahrling, P. B., Burton, D. R. (2002). Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. J. Virol. 76: 6408-6412 [Abstract] [Full Text]  
  • Mascola, J. R., Louder, M. K., Winter, C., Prabhakara, R., De Rosa, S. C., Douek, D. C., Hill, B. J., Gabuzda, D., Roederer, M. (2002). Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. J. Virol. 76: 4810-4821 [Abstract] [Full Text]  
  • Nishimura, Y., Igarashi, T., Haigwood, N., Sadjadpour, R., Plishka, R. J., Buckler-White, A., Shibata, R., Martin, M. A. (2002). Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies. J. Virol. 76: 2123-2130 [Abstract] [Full Text]  
  • Bures, R., Morris, L., Williamson, C., Ramjee, G., Deers, M., Fiscus, S. A., Abdool-Karim, S., Montefiori, D. C. (2002). Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. J. Virol. 76: 2233-2244 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»